Veru Inc. (VERU)
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
$117.28M
Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D.
233.00
Miami, FL
Jul 19, 1990
-2.67
$-0.30
0.59
1.56
-734.47%
-0.80
-0.01
2.56
6.00
1.08
-146.74%
-243.80%
Similar stocks (11)
Sarepta Therapeutics, Inc.
SRPT
Axsome Therapeutics, Inc.
AXSM
Iovance Biotherapeutics, Inc.
IOVA
Novavax, Inc.
NVAX
Lexicon Pharmaceuticals, Inc.
LXRX
Anavex Life Sciences Corp.
AVXL
2seventy bio, Inc.
TSVT
Seres Therapeutics, Inc.
MCRB
Puma Biotechnology, Inc.
PBYI
Annovis Bio, Inc.
ANVS
Protalix BioTherapeutics, Inc.
PLX
ETF Exposure (21)
iShares Micro-Cap ETF
IWC
0.03172%
Vanguard Russell 2000 Growth Index Fund
VTWG
0.01%
iShares Russell 2000 Growth ETF
IWO
0.00674%
iShares Russell 2000 ETF
IWM
0.00434%
iShares Russell 2000 Value ETF
IWN
0.00245%
ProShares Ultra Russell2000
UWM
0.0017138808008895314%
ProShares UltraPro Russell2000
URTY
8.445908298236131e-4%
ProShares Hedge Replication ETF
HDG
7.170227689465485e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Russell 2000 Index Fund
VTWO
0%
Vanguard Russell 2000 Value Index Fund
VTWV
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (11)
Sarepta Therapeutics, Inc.
SRPT
Axsome Therapeutics, Inc.
AXSM
Iovance Biotherapeutics, Inc.
IOVA
Novavax, Inc.
NVAX
Lexicon Pharmaceuticals, Inc.
LXRX
Anavex Life Sciences Corp.
AVXL
2seventy bio, Inc.
TSVT
Seres Therapeutics, Inc.
MCRB
Puma Biotechnology, Inc.
PBYI
Annovis Bio, Inc.
ANVS
Protalix BioTherapeutics, Inc.
PLX
ETF Exposure (21)
iShares Micro-Cap ETF
IWC
0.03172%
Vanguard Russell 2000 Growth Index Fund
VTWG
0.01%
iShares Russell 2000 Growth ETF
IWO
0.00674%
iShares Russell 2000 ETF
IWM
0.00434%
iShares Russell 2000 Value ETF
IWN
0.00245%
ProShares Ultra Russell2000
UWM
0.0017138808008895314%
ProShares UltraPro Russell2000
URTY
8.445908298236131e-4%
ProShares Hedge Replication ETF
HDG
7.170227689465485e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Russell 2000 Index Fund
VTWO
0%
Vanguard Russell 2000 Value Index Fund
VTWV
0%
Vanguard Extended Market Index Fund
VXF
0%